The MedTech Intelligence Industry Survey is a primary research initiative designed to capture the perspectives of professionals working across the medical technology sector. The study is intended to ...

How MedTech manufacturers can move cybersecurity upstream, strengthen traceability, and prepare for faster vulnerability ...

GenAI-enabled medical devices hold transformative promise for patient care and the broader health ecosystem. At the same time, these devices may introduce unique risks when compared to traditional ...

As medical devices become increasingly connected and software-driven, cybersecurity cannot be treated as a final compliance checkpoint. It must be integrated throughout the entire product lifecycle, ...

Medical device software development teams have always struggled with a deceptively simple question: How much of the system is actually complete? Project dashboards, requirements databases, sprint ...

Post-market surveillance (PMS) systems in the medical device industry have become increasingly sophisticated in collecting complaints, monitoring adverse events, and generating regulatory reports.

Artificial intelligence is already inside regulatory affairs functions across the medtech industry. Teams are using it to summarize guidance documents, support first-pass drafting, compare labeling ...

CMS’s proposed expansion of Medicare TAVR coverage to include select asymptomatic severe aortic stenosis patients and reduce access barriers for symptomatic patients could significantly increase TAVR ...

Medtronic reported robust fiscal 2026 results, fueled by strong growth in cardiovascular, medical surgical, and diabetes technologies, while advancing key product launches, regulatory milestones, and ...

The most recent AI thought leadership published on MedTechIntelligence.com. We are seeing it everywhere, Artificial Intelligence in our daily activities – smart thermostats and smart lights in our ...

Market Access is now the central input into M&A and value-driven divestitures, enabling MedTech leaders to reshape portfolios for strategic advantage, long-term growth, and greater value to patients – ...

Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions and solidifies Natera’s Treatment on MRD (TOMR) approach for MIBC care. Natera, ...